drugset / Trial / NCT00283465

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

NCT00283465 ↗

Phase 4 Completed 316 enrolled Janssen-Cilag B.V.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effectiveness of early treatment of anemia with epoetin alfa (a glycoprotein that stimulates red blood cell production) or best standard anemia care on the need for blood transfusions, tumor response, anemia and quality of life in patients with cancer receiving platinum-containing chemotherapy.

Timeline

Start
1999-11
Primary completion
—
Completion
2004-04

Outcome

Met primary endpoint

paper EPO therapy significantly decreased transfusion requirements (P < 0.001) PMID 15953714 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous

Indications